Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives (Q34635520)

3 August 2017

1 reference

title

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives (English)

1 reference

3 August 2017

2

Baptist Gallwitz

0 references

author name string

Juris J Meier

series ordinal

1

1 reference

3 August 2017

Wolfgang E Schmidt

series ordinal

3

1 reference

3 August 2017

Michael A Nauck

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

European Journal of Pharmacology

3 August 2017

1 reference

3 August 2017

440

1 reference

3 August 2017

2-3

1 reference

3 August 2017

269-279

1 reference

Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Hamster preproglucagon contains the sequence of glucagon and two related peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Inhibition of food intake by inhibitors of fatty acid synthase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Identification of the intestinal cell storing gastric inhibitory peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

The incretin concept today

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide-1(7-36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Structure/activity characterization of glucagon-like peptide-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide-1: a potent regulator of food intake in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Role of GLP-1 in meal-taking.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide-1 7-36: a physiological incretin in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Characterization of glucagon-like peptide-1-(7-36)amide in the hypothalamus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Gut-type glucagon immunoreactivity in nerves of the rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Chromatographic resolution and kinetic characterization of glucokinase from islets of Langerhans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Attenuated GLP-1 secretion in obesity: cause or consequence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Gastric emptying and release of incretin hormones after glucose ingestion in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Model for the regulation of energy balance and adiposity by the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Central nervous system control of food intake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

The central neural connections of the area postrema of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Identification and localization of glucagon-like peptide-1 and its receptor in rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Biological activity of GLP-1-analogues with N-terminal modifications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Identification and localization of glucagon-related peptides in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

A role for glucagon-like peptide-1 in the central regulation of feeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucagon-like peptide 1: a potent glycogenic hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Distribution of GLP-1 and PACAP receptors in human tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901434-6

10.1016/S0014-2999(02)01434-6

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference